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hormone oestradiol reduces microglia inflammatory activity.
The objective of this study was to test whether two selective
oestrogen receptor modulators, tamoxifen and raloxifene,
modulate in vivo the activation of microglia induced by the
peripheral administration of lipopolysaccharide (LPS). Acti-
vation of microglia was assessed in the white matter of the
cerebellum using immunoreactivity for major histocompat-
ability complex-II. Oestradiol, tamoxifen and raloxifene
decreased microglia activation induced by LPS in male and
ovariectomized female rats, although the doses of oestradiol
that were effective in decreasing microglia reactivity were not
the same in both sexes. Tamoxifen reduced microglia
activation in all experimental groups at all doses tested
(0.5–2 mg/kg b.w.) while raloxifene lost its anti-inflam-
matory activity at the higher dose tested (2 mg/kg b.w). InJournal of Endocrinology (2008) 198, 219–230
0022–0795/08/0198–219 q 2008 Society for Endocrinology Printed in Greataddition, raloxifene had per se a moderate pro-inflammatory
activity in the brain of control female rats and its anti-
inflammatory activity was partially impaired in female animals
after 1 month of deprivation of ovarian hormones. Spots of
oestrogen receptor (ER)-a immunoreactivity were detected
in the soma and cell processes of microglia. Treatment with
LPS, oestradiol or tamoxifen induced an increase of ER-a
immunoreactive spots in the perikaryon of microglia, while
oestradiol antagonized the effect of LPS. The results indicate
that some oestrogenic compounds decrease brain inflam-
mation by a mechanism that may involve ERs expressed by
microglia. The findings support the potential therapeutic role
of oestrogenic compounds as protective anti-inflammatory
agents for the central nervous system.
Journal of Endocrinology (2008) 198, 219–230Introduction
The central nervous system is a target for the ovarian
hormone oestradiol, a key regulator of reproductive
physiology. Oestradiol acts in different regions of the brain
and the spinal cord controlling neuroendocrine secretions,
reproductive behaviours and non-reproductive events, modu-
lating synaptic function and plasticity, and affecting mood and
cognition (Fink et al. 1996, McEwen et al. 1997, Woolley
2007). In addition, oestradiol is a neuroprotective factor that
promotes neuronal survival and tissue integrity in different
experimental models of neurodegeneration (Garcia-Segura
et al. 2001, Maggi et al. 2004, Suzuki et al. 2006).
Recent studies suggest that at least part of the neuropro-
tective effects of oestradiol may be exerted by reducing brain
inflammation acting on microglia. Oestradiol has been shown
to inhibit the expression of inflammatory mediators by
microglia in vitro (Bruce-Keller et al. 2000, 2001, Drew &
Chavis 2000, Vegeto et al. 2001, Baker et al. 2004, Dimayuga
et al. 2005) and to reduce microglia reactivity in vivo in
different models of brain inflammation (Vegeto et al. 2003,2006) and brain injury (Barreto et al. 2007). These actions
may be highly relevant for the neuroprotective actions of the
hormone. Activation of microglia is a normal response from
neural tissue to cope with infections and neurodegeneration
and is oriented to protect neural tissue. However, exaggerated
and chronic activation of microglia may lead to neurotoxicity
and may be detrimental for neural tissue (Thomas 1992,
Streit et al. 1999, Polazzi & Contestabile 2002, Depino
et al. 2003, Kim & de Vellis 2005, Marchetti & Abbracchio
2005, Minghetti 2005, Suzumura et al. 2006, Block et al.
2007). Therefore, the regulation of the response of microglial
cells to inflammation may represent a therapeutic approach to
control neurodegeneration.
Oestrogen receptors (ERs) are candidate targets for possible
neuroprotective and anti-inflammatory therapies based on
oestrogen actions. The activity of ERs is regulated by their
association with transcriptional cofactors that have a tissue- or
cell-specific expression (Klinge 2000, McKenna & O’Malley
2002, Belandia & Parker 2003). This association depends on the
three-dimensional conformation of the receptors (Norris et al.
1999), which is modified by different oestrogenic ligandsDOI: 10.1677/JOE-07-0294
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several ER ligands, known as selective ER modulators
(SERMs), are able to exert tissue- and cellular-specific
inductions or repressions of the activity of ERs, acting as ER
agonists in some tissues and as antagonists in others. SERMs
may therefore represent an alternative to oestradiol for the
treatment or prevention of neurodegenerative disorders (Cyr
et al. 2000, Dhandapani & Brann 2002, Littleton-Kearney et al.
2002, Kimelberg et al. 2003, Murphy et al. 2003, Brinton 2004,
DonCarlos et al. 2007, Prokai & Simpkins 2007), since theymay
have oestrogenic neuroprotective actions in the brain and
absence of oestrogenic actions, or even anti-oestrogenic effects,
in other tissues, avoiding the peripheral risks associated with
oestrogen therapy. A previous study has shown that two SERMs
of clinical use in humans, tamoxifen and raloxifene, are able to
reducemicroglia activation in vitro (Suuronen et al. 2005). In this
study, we have assessed the anti-inflammatory effects of 17b-
oestradiol, tamoxifen and raloxifene, in an in vivo model of
microglia activation induced by the peripheral administration of
the bacterial endotoxin lipopolysaccharide (LPS). Our findings
indicate that 17b-oestradiol, tamoxifen and raloxifene exert
anti-inflammatory actions on central nervous system microglia
in response to peripheral inflammation and suggest that part of
these effects may be exerted directly on microglial cells
expressing ERa.Materials and Methods
Animals and experimental treatments
Wistar albino male and female rats from the animal colony of
Complutense University were kept in a 12:12 h light/dark
schedule and received food and water ad libitum. Animals were
handled in accordance with the guidelines presented in the
UFAW Handbook on the Care and Management of
Laboratory Animals (Poole 1999) and following the European
Union guidelines (Council Directive 86/609/EEC). Experi-
mental procedures were approved by our institutional animal
use and care committee. Special care was taken to minimize
suffering and to reduce the number of animals used to the
minimum required for statistical accuracy. Females were
bilaterally ovariectomized under halothane anaesthesia
(Fluothane, AstraZeneca Farmace´utica, Madrid, Spain) to
eliminate the influence of cycling changes in ovarian
secretions on microglia.
Three-month-old gonadally intact male rats and ovari-
ectomized females (1 week or 1 month after ovariectomy),
received a first i.p. injection of an oestrogenic compound (see
below) and 1 h later a first i.p. injection of 1 mg/kg b.w. LPS
from Escherichia coli 055:B5 (L2880, Sigma–Aldrich) dissolved
in PBS.After 3 days, the animals received a second i.p. injection
of the oestrogenic compound and 1 h later a second i.p.
injection of LPS (1.33 mg/kg b.w). The pattern and doses
of administration of LPS were based on a previous study
(Ng & Ling 1997). The control rats received injections ofJournal of Endocrinology (2008) 198, 219–230vehicles. Some animals were injected with oestrogenic
compounds and the vehicle for LPS and some animals
received injections of LPS and the vehicle for oestrogenic
compounds. The oestrogenic compounds tested were:
17b-oestradiol (E2758, Sigma; 50, 250, 500 and 700 mg/kg
b.w.), tamoxifen (T5648, Sigma; 0.5, 1 and 2 mg/kg b.w.) and
raloxifene (R1402, Sigma; 0.5, 1 and 2 mg/kg b.w). The
oestrogenic compounds were dissolved in 40 ml/mg dimethyl-
sulphoxide (Sigma) in 0.9% NaCl (pH 7.4) and were injected
at doses that in previous studies resulted in neuroprotective
effects (Picazo et al. 2003, Ciriza et al. 2004).Tissue fixation and immunohistochemistry
Four days after the second injection of LPS, animals were
deeply anaesthetized with pentobarbital (50 mg/kg, Normon
Veterinary Division, Madrid, Spain) and perfused through the
left cardiac ventricle, first with 50 ml saline solution (0.9%
NaCl) and then with 250 ml fixative solution (4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4). Brains
were removed and immersed for 4–6 h at 4 8C in the same
fixative solution and then rinsed with phosphate buffer.
Sagittal sections of the cerebellum, 50 mm thick, were
obtained using a vibratome (VT 1000S, Leica Microsystems,
Wetzlar, Germany).
Immunohistochemistry was carried out in free-floating
sections under moderate shaking. The endogenous peroxidase
activity was quenched for 10 min at room temperature in a
solution of 3% hydrogen peroxide in 30% methanol. After
several washes in 0.1 M phosphate buffer (pH 7.4), containing
0.3%BSA, 0.3%TritonX-100and0.9%NaCl (washing buffer),
sections were incubated overnight at 4 8C with one of the
following primary antibodies: amousemonoclonal antibody for
major histocompatability complex-II (MHC-II; MRC-OX6,
MCA46G, Serotec, Bicester, UK; diluted 1:300); a mouse
monoclonal antibody for OX42 (MCA275G, Serotec; diluted
1:300); a mouse anti-rat lysosomal enzyme (anti CD68, ED1,
Serotec; diluted 1:1000); a rabbit polyclonal antibody for ERa
(MC20, sc 542, raised against an epitope mapping at the
C-terminus of ERa of mouse origin, Santa Cruz Bio-
technology,Madrid, Spain; diluted 1:300) or a rabbit polyclonal
antibody for ERb (51-7900, Zymed, Barcelona, Spain; diluted
1:500). Primary antibodies were diluted in washing buffer
containing 3% normal goat serum. To amplify the immuno-
reactive signal of ERa and ERb antibodies, the tyramide signal
amplification kit (TSA Biotin System NEL700; NEN Life
Science Products) was used in some incubations according to
the manufacturer’s instructions. After incubation with the
primary antibody, sections were then rinsed in buffer and
incubated for 2 h at room temperature with biotinylated goat
anti-mouse immunoglobulin G (31800 Pierce, Rockford, IL,
USA; diluted 1:250 in washing buffer) or biotinylated goat
anti-rabbit immunoglobulin G (31820 Pierce; diluted 1:250 in
washing buffer). After several washes in buffer, sections were
incubated for 90 min at room temperature with avidin–biotin-
peroxidase complex (ImmunoPure ABC peroxidase stainingwww.endocrinology-journals.org
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product was revealed by incubating the sections with 2 mg/ml
3,3’-diaminobenzidine (Sigma–Aldrich) and 0.01% hydrogen
peroxide in 0.1 M phosphate buffer. Then, sections were
dehydrated, mounted on gelatinized slides and observed in a
Leica DMRBE microscope.
The possible expression of ERs by microglia was assessed by
immunofluorescence using a mouse monoclonal antibody for
OX42 (MCA275G, Serotec; diluted 1:300), which recognizes
both resting and activatedmicroglia, in combinationwithone of
the following antibodies: a rabbit polyclonal antibody for ERa
(MC20, sc 542, Santa Cruz Biotechnology; diluted 1:300); a
rabbit polyclonal antibody for ERb (51-7900, Zymed; diluted
1:250) or a primary chicken polyclonal antibody for ERb
(14021Abcam,Cambridge,UK; diluted 1:200). The secondary
antibodies used were the following: red Alexa-conjugated goat
anti-mouse antibody (A-11020, Molecular Probes, Madrid,
Spain; diluted 1:1000), green Alexa-conjugated goat anti-rabbit
antibody (A-11008, Molecular Probes; diluted 1:1000) and
green Alexa-conjugated goat anti-chicken antibody (703-096-
155, Jackson ImmunoResearch Laboratories, Inc., Madrid,
Spain). After several washes in buffer, sectionsweremounted on
histological slides, air-dried overnight at room temperature and
cover slipped with an anti-fading water-based medium. The
sections were observed using a Leica TCS4D confocal scanner
installed in a Leitz DM1RB microscope.Morphometric analysis
Number of MHC-II and OX42 immunoreactive
cells Preliminary studies showed abundant MHC-II and
OX42 immunoreactive cells in the brain white matter tracts
and regions of the animals treated with LPS. MHC-II and
OX42 immunoreactive cells were highly abundant in the
cerebellar white matter, both in the central white matter
and in the molecular layer of the cerebellar cortex. The
cerebellum was therefore selected for the morphometrical
analysis of microglia.
The number of MHC-II and OX42 immunoreactive cells
was assessed in the central white matter of the cerebellum in a
region dorsal and anterior to the lateral cerebellar nucleus,
located between the lobes 2–5 and at a lateral distance of
w2.4–2.9 mm from the midline, according to the stereotaxic
atlas of the rat brain by Paxinos & Watson (1986). The
number of immunoreactive cells was estimated by the optical
disector method (Howard & Reed 1998) using total section
thickness for disector height (Hatton & von Bartheld 1999)
and a counting frame of 220!220 mm. A total of 60 counting
frames were assessed per animal. Section thickness was
measured using a digital length gauge device (Heidenhain-
Metro MT 12/ND221; Traunreut, Germany) attached to the
stage of a Leitz microscope. Cell nuclei from immunoreactive
cells that came into focus while focusing down through the
dissector height were counted. All counts were performed on
coded sections. The volume of the central white matter of the
cerebellum was estimated according to the Cavalieri’swww.endocrinology-journals.orgprinciple using the point-counting method of Weibel
(1979). Since no significant differences in this parameter
were observed among the different experimental groups, the
changes in the number of immunoreactive cells per unit
volume with the optical disector method are assumed to
reflect changes in the immunoreactive cell content.
Colocalization of ERa and OX42 For each animal, the
percentage of OX42 immunoreactive cells showing ERa
immunoreactivity in the central white matter of the cerebellum
was estimated on microphotographs covering a total area of
0.1 mm2. Sections immunostained for both ERa and OX42
(red andgreenchannels respectively)werephotographed at 40!
magnification in a Leica DMI 6000B microscope. Points of
colocalizationof red andgreen channelswere identifiedonRGB
images with the aid of the colocalization plugin of the Image J
software (developed at theUSANational Institutes ofHealth and
available on the Internet at http://rsb.info.nih.gov/ij/). The
points of colocalization identified by the Image J software were
confirmed by visual inspection of the images. Then, the number
of OX42 immunoreactive perikarya showing points of ERa
immunoreactivity and the total number of OX42 immuno-
reactive perikarya were counted in each image to estimate the
percentage of cell perikarya that colocalized OX42 and ERa.Statistical analysis
The n used for statistical analysis was the number of animals
indicated in the figure legends. Four animals from each
experimental group were evaluated for immunohisto-
chemical colocalization of ERa and OX42. Since the F-test
did not reveal significant differences between variances, data
were analysed with ANOVA followed by the Tukey test, with
P!0.05 considered to be significant.Results
Effects of LPS on glial cell markers
Few MHC-II immunoreactive cells were detected in the
cerebellum of control rats and obvious qualitative differences
in the amount and morphology of immunoreactive cells were
observed between the different experimental groups (Figs 1, 3
and 5). MHC-II immunoreactive cells were much more
abundant (Figs 1, 3 and 5) and showed larger somas, and
retracted and thicker processes (compare inserts in Figs 1A, E
and 3A, E) in the animals injected with LPS than in control
animals injected with vehicles. Similar qualitative differences
to those observed with the MHC-II antibody were also
detected in sections immunostained with the ED1 antibody, a
marker of phagocytic microglia (not shown). The number of
MHC-II immunoreactive cells, estimated with the optical
dissector method, was significantly increased after LPS
administration in both male and female animals (Figs 2, 4
and 6). By contrast, LPS treatment did not affect the totalJournal of Endocrinology (2008) 198, 219–230
Figure 1 Representative images of the central white matter of the
cerebellum of male rats showing immunoreactivity for MHC-II after
the following treatments: (A) vehicles for oestrogenic compounds
(DMSO) and LPS (phosphate buffer); (B) 17b-oestradiol, 250 mg/kg
b.w.; (C) tamoxifen,1 mg/kg b.w.; (D) raloxifene, 1 mg/kg b.w.; (E) LPS;
(F) 17b-oestradiol, 250 mg/kgb.w.andLPS; (G) tamoxifen,1 mg/kgand
LPS; and (H) raloxifene, 1 mg/kg and LPS. Inserts show details of the
morphology of MHC-II immunoreactive cells at high magnification.
Scale bar, 100 mm. In the inserts, the scale bar represents 25 mm.
Figure 2 Number ofMHC-II immunoreactivecells/mm3 in the central
white matter of the cerebellum of male rats after the following
treatments: vehicles for oestrogenic compounds and LPS (Control,
nZ10); oestradiol, 250 mg/kg b.w. (Oestradiol 250, nZ4); tamoxifen,
1 mg/kg. b.w. (Tamoxifen 1, nZ4); raloxifene, 1 mg/kg b.w.
(Raloxifene 1, nZ4); LPS (LPS and Vehicle, nZ16); LPS and
oestradiol, 50 mg/kg b.w. (LPS and Oestradiol 50, nZ6); LPS and
oestradiol, 250 mg/kg b.w. (LPS and Oestradiol 250, nZ5); LPS
and oestradiol, 500 mg/kg b.w. (LPS and Oestradiol 500, nZ8);
LPS and oestradiol, 700 mg/kg b.w. (LPS and Oestradiol 700, nZ5);
LPS and tamoxifen, 0.5 mg/kg (LPS and Tamoxifen 0.5,nZ6); LPS and
tamoxifen, 1 mg/kg (LPS and Tamoxifen 1, nZ6); LPS and tamoxifen,
2 mg/kg (LPS and Tamoxifen 2, nZ6); LPS and raloxifene, 0.5 mg/kg
(LPS and Raloxifene 0.5, nZ4); LPS and raloxifene, 1 mg/kg (LPS and
Raloxifene 1, nZ8); LPS and raloxifene, 2 mg/kg (LPS and Raloxifene
2, nZ4). Data are meanGS.E.M. Significant differences versus LPS
values: *P!0.05; **P!0.01; ***P!0.001. Significant differences
versus control values: ^P!0.05; ^^^P!0.001.
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marker OX42 (males: controls, 6906G413, nZ10; LPS,
8571G272, nZ19; females: controls, 7258G414, nZ9; LPS,
8116G222, nZ19. Data are cells/mm3). Furthermore, the
number of OX42 immunoreactive cells was not affected by
the experimental treatments with oestrogenic compounds,
either in animals treated with LPS or vehicle (not shown).Effects of oestrogenic compounds on MHC-II immunoreactive
microglia in male rats
Administration of 17b-oestradiol tomale rats resulted in a dose-
dependent decrease in the number ofMHC-II immunoreactive
cells (Figs 1 and 2). Animals injected with LPS and treated with
oestradiol at the doses of 50 and 250 mg/kg b.w. showed aJournal of Endocrinology (2008) 198, 219–230decrease in the number of MHC-II cells to values that were
significantly lower than those of animals injectedwithLPS alone
and were not significantly different from control values. In
addition,MHC-II immunoreactive cells in the animals injected
with oestradiol at the doses of 50 and 250 mg/kg b.w. and LPS
showed longer and thinner cellular processes and smaller cell
somas than in the animals injected with LPS alone (compare
inserts in Fig. 1E and F). Higher doses of oestradiol were unable
to significantly reduce the number ofMHC-II immunoreactive
cells in LPS-injected animals. Oestradiol, tested at the dose of
250 mg/kg b.w., did not significantly affect MHC-II immunor-
eactivity in animals not treated with LPS (Figs 1 and 2).
In contrast to the dose-dependent effect of oestradiol, all the
doses of tamoxifen tested in LPS-injected animals (ranging from
0.5 to 2 mg/kg) were able to significantly reduce the number of
MHC-II immunoreactive cells when compared with the values
of animals injected with LPS alone (Figs 1 and 2). MHC-II
immunoreactive cells showed longer and thinner cellular
processes and smaller cell somas in the animals injected with
tamoxifen and LPS when compared with animals injected with
LPS alone (compare inserts in Fig. 1E and G). Raloxifene was
also able to significantly reduce the reactive morphology of
MHC-II immunoreactive cell (compare inserts in Fig. 1E and
H) and their number, in LPS-injected animals in comparison
with the animals injectedwithLPSalone, butonlyat the doses ofwww.endocrinology-journals.org
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(tested at 1 mg/kg b.w.), in absence of LPS, did not affect the
number of MHC-II immunoreactive cells (Figs 1 and 2).Figure 3 MHC-II immunoreactivity in the central white matter of
the cerebellum of female rats in which treatments with oestrogenic
compounds and LPS were initiated 1 week after ovariectomy. The
figures show representative images after the following treatments:
(A) vehicles; (B) 17b-oestradiol, 250 mg/kg b.w.; (C) tamoxifen,
1 mg/kg b.w.; (D) raloxifene, 1 mg/kg b.w.; (E) LPS; (F) 17b-
oestradiol, 250 mg/kg b.w. and LPS; (G) tamoxifen, 1 mg/kg and LPS;
and (H) raloxifene, 1 mg/kg and LPS. Inserts show details of the
morphology of MHC-II immunoreactive cells at high magnification.
Scale bar, 100 mm. In the inserts, the scale bar represents 25 mm.Effects of oestrogenic compounds on MHC-II immunoreactive
microglia in female rats when the treatments were initiated 1 week
after ovariectomy
Having established that oestrogenic compounds were able to
reduce the effect of LPS on the number of MHC-II
immunoreactive cells in the cerebellum of male rats, in a
second series of experiments we assessed whether these
compounds had similar effects in females. Female rats were
ovariectomized to eliminate the fluctuation of ovarian
hormones during the oestrous cycle. In a first experiment,
the treatment with LPS and oestrogenic compounds were
initiated 1 week after ovariectomy. As in males, oestradiol
administration to LPS-injected females decreased, in a dose-
dependent manner, the number of MHC-II to control values
(Figs 3 and 4).Oestradiol also reduced the reactivemorphology
of microglia (compare inserts in Fig. 3E and F). However, in
contrast to males, the lower dose of oestradiol tested (50 mg/kg
b.w.) did not significantly reduce the number of MHC-II cells
in LPS-injected animals. By contrast, both the doses of 250 and
500 mg/kg b.w. resulted in a significant decrease in the number
of MHC-II immunoreactive cells (Figs 3 and 4). Oestradiol,
tested at the dose of 250 mg/kg b.w., did not significantly affect
MHC-II immunoreactivity in animals that were not treated
with LPS (Figs 3 and 4).
As observed in male rats, all the tested doses of tamoxifen
resulted in a reduction in the reactive morphology of
microglia (see inserts in Fig. 3E and G) and decreased the
number of MHC-II in LPS-injected animals to values that
were not significantly different from those of control animals
injected with vehicles (Figs 3 and 4). The maximal effect was
observed with the dose of 1 mg/kg. Raloxifene, at doses of
0.5 and 1 mg/kg b.w. reduced the number of MHC-II
immunoreactive cells to control levels and decreased the
reactive morphology of microglia (compare inserts in Fig. 3E
and H). However, at a higher dose (2 mg/kg b.w.), raloxifene
did not significantly modify the number of MHC-II
immunoreactive cells in comparison with the animals injected
with LPS alone (Fig. 4). The administration of tamoxifen
(1 mg/kg b.w.) or raloxifene (1 mg/kg b.w.) to ovari-
ectomized females that were not treated with LPS did not
significantly affect the number of MHC-II immunoreactive
cells in comparison with the control values (Figs 3 and 4).
However, raloxifene had a moderate inflammatory effect not
observed in males, since MHC-II immunoreactive cells in
animals injected with raloxifene, in absence of LPS, showed
morphological characteristics of reactive microglia, with
thicker cell bodies and cellular processes (compare inserts in
Fig. 3A and D). In addition, the number of MHC-II
immunoreactive cells after the administration of raloxifene, in
absence of LPS, was not significantly different to the values of
the LPS group (Fig. 4).www.endocrinology-journals.orgEffects of oestrogenic compounds on MHC-II immunoreactive
microglia in female rats when the treatments were initiated
1 month after ovariectomy
In a second group of female rats, the treatments with LPS and
oestrogenic compounds were initiated 1 month after ovari-
ectomy to determine whether differences in previous duration
of ovarian hormone deprivation may affect the response of
MHC-II cells (Figs 5 and 6). In animals injected with LPS 1
month after ovariectomy, both oestradiol (250 mg/kg b.w.) and
tamoxifen (0.5 and 1 mg/kg b.w.) decreased the number of
MHC-II immunoreactive cells tovalues significantly lower than
in the animals injected with LPS alone (Figs 5 and 6). As
observed in female rats when the treatments were initiated 1Journal of Endocrinology (2008) 198, 219–230
Figure 4 Number ofMHC-II immunoreactivecells/mm3 in the central
white matter of the cerebellum of female rats in which treatments with
oestrogenic compounds and LPS were initiated 1 week after
ovariectomy. Treatments and the number of animals studied for each
treatment are as follows: vehicles (Control, nZ9); oestradiol,
250 mg/kg b.w. (Oestradiol 250, nZ4); tamoxifen, 1 mg/kg. b.w.
(Tamoxifen 1, nZ4); raloxifene, 1 mg/kg b.w. (Raloxifene 1, nZ4);
LPS (LPS and Vehicle, nZ16); LPS and oestradiol, 50 mg/kg b.w.
(LPS and Oestradiol 50,nZ4); LPS and oestradiol, 250 mg/kg b.w. (LPS
and Oestradiol 250, nZ5); LPS and oestradiol, 500 mg/kg b.w. (LPS
and Oestradiol 500, nZ5); LPS and tamoxifen, 0.5 mg/kg (LPS and
Tamoxifen 0.5, nZ5); LPS and tamoxifen, 1 mg/kg (LPS and
Tamoxifen 1, nZ4); LPS and tamoxifen, 2 mg/kg (LPS and Tamoxifen
2, nZ5); LPS and raloxifene, 0.5 mg/kg (LPS and Raloxifene 0.5,
nZ4); LPS and raloxifene, 1 mg/kg (LPS and Raloxifene 1, nZ4); LPS
and raloxifene, 2 mg/kg (LPS and Raloxifene 2, nZ4). Data are
meanGS.E.M. Significant differences versus LPS values: *P!0.05;
**P!0.01; ***P!0.001. Significant differences versus control values:
^^P!0.01; ^^^P!0.001.
Figure 5 MHC-II immunoreactivity in the central white matter of
the cerebellum of female rats in which treatments with oestrogenic
compounds and LPS were initiated 1 month after ovariectomy. The
figures show representative images after the following treatments:
(A) vehicles; (B) LPS; (C) 17b-oestradiol, 250 mg/kg b.w. and LPS; (D)
tamoxifen, 1 mg/kg and LPS; (E) raloxifene, 0.5 mg/kg and LPS; (F)
raloxifene, 1 mg/kg and LPS. Scale bar, 100 mm.
Figure 6 Number of MHC-II immunoreactive cells/mm3 in the
central white matter of the cerebellum of female rats in which
treatments with oestrogenic compounds and LPS were initiated
1 month after ovariectomy. Treatments and the number of animals
studied for each treatment are as follows: vehicles (Control, nZ10);
S TAPIA-GONZALEZ and others . Oestrogenic compounds reduce brain inflammation224week after ovariectomy, the maximal effect of tamoxifen was
observedwith a dose of 1 mg/kgb.w.Therefore, the response of
MHC-II immunoreactive cells to oestradiol and tamoxifen was
similar after 1 month and 1 week of ovariectomy. Raloxifene, at
the dose of 0.5 mg/kg b.w., also resulted in a significant
reduction in the number of MHC-II immunoreactive cells, as
observed in female rats when the treatments were initiated 1
week after ovariectomy (Figs 5 and 6). However, the anti-
inflammatory effect of raloxifenewas loss at the dose of 1 mg/kg
b.w. in female animals injected with LPS 1 month after
ovariectomy. The number of MHC-II cells in animals injected
with LPS and raloxifene at the dose of 1 mg/kgwas significantly
increased in comparison with the control values and was not
significantly different from the values of animals injected with
LPS alone (Fig. 6). Therefore, the anti-inflammatory effect of
raloxifenewas partially impaired after 1month of deprivation of
ovarian hormones.LPS (LPS and Vehicle, nZ9); LPS and oestradiol, 250 mg/kg b.w.
(LPS and Oestradiol 250, nZ3); LPS and tamoxifen, 0.5 mg/kg
and LPS (Tamoxifen 0.5, nZ5); LPS and tamoxifen, 1 mg/kg
(LPS and Tamoxifen 1, nZ4); LPS and raloxifene, 0.5 mg/kg (LPS
and Raloxifene 0.5, nZ4); LPS and raloxifene, 1 mg/kg (LPS and
Raloxifene 1, nZ4). Data are meanGS.E.M. Significant differences
versus LPS values: *P!0.05; ***P!0.001. Significant differences
versus control values: ^P!0.05; ^^^P!0.001.Expression of ERs in microglia
The possible expression of ERs in microglia was explored by
immunohistochemistry. As expected from previous reports
(Shughrue et al. 1997, Price & Handa 2000), ERb immunor-
eactivity was observed in the Purkinje cells (Fig. 7). However,Journal of Endocrinology (2008) 198, 219–230 www.endocrinology-journals.org
Figure 7 Immunostaining in Purkinje cells (arrow) using the rabbit
polyclonal antibody for ERb. mol, molecular layer; gcl, granule cell
layer. Scale bar, 25 mm.
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immunoreactivity with the microglial marker OX42, neither in
control animals injected with vehicles nor in animals injected
with oestrogenic compounds, LPS or the combination of LPS
and oestrogenic compounds. Identical results were obtained
with the two ERb antibodies tested.
By contrast, ERa immunoreactivity was colocalized with
OX42 (Fig. 8). Under basal conditions, the pattern of ERa
immunoreactivity was diffused and in a first examination, in
control animals, we considered the staining as background
(Fig. 8D). However, in animals treated with LPS 1 week after
ovariectomy, ERa immunoreactivity clearly delineated cell
somas (Fig. 8H) and punctiform ERa immunostaining in the
cell perikarya and processes of OX42 immunoreactive cells
was evident (Fig. 8G). The punctiform staining was not
observed when the incubation with the primary ERa
antibody was omitted. As a control of the specificity of the
ERa signal, we used sections from ERaKO mice from
another study in which microglia activation was induced by a
stab wound in the cerebral cortex and the hippocampus. ERa
immunoreactivity was not detected in OX42 immunoreactive
cells from ERaKO mice (not shown).
The estimation of the percentage of OX42 immuno-
reactive perikarya showing ERa immunostaining revealed
a significant increase in animals treated with LPS 1 week
after ovariectomy (67G5 vs 88G3% in controls and LPS-
injected animals respectively; S.D., P!0.01). Treatment with
oestradiol (250 mg/kg) also increased the localization of
ERa immunoreactive spots in the perikaryon of OX42
immunoreactive cells and the percentage of colocalization
under basal conditions in the absence of LPS (87G0.5%; S.D.,
P!0.01 versus control values). However, oestradiol treat-
ment counteracted the effect of LPS on the percentage of
colocalization (73G2%; S.D., P!0.01 versus LPS values). As
observed for oestradiol, tamoxifen treatment (1 mg/kg b.w.)
increased the percentage of OX42 immunoreactive cells withwww.endocrinology-journals.orgERa immunostaining under basal conditions (93G1%; S.D.,
P!0.05 versus control values). However, tamoxifen did not
significantly affect the percentage of colocalization in the
animals injected with LPS (81G8%). Raloxifene (1 mg/kg
b.w.) did not significantly affect the percentage of OX42
immunoreactive cells with ERa immunostaining under basal
conditions and did not significantly modify the colocalization
in LPS-injected animals (not shown). Different results were
obtained when the treatments were initiated 1 month after
ovariectomy. Under these conditions, the percentage of cells
colocalizing ERa and OX42 was not significantly affected by
LPS or by the combination of LPS and oestradiol or LPS and
tamoxifen (50G3, 37G5, 52G8, and 46G6% in animals
treated with vehicle, LPS, oestradiol and LPS, and tamoxifen
and LPS respectively). By contrast, the combination of LPS
and raloxifene induced a significant decrease in the percentage
of cells colocalizing ERa and OX42 when compared with
vehicle values (36G1%; S.D., P!0.01). Furthermore, the
basal percentage of OX42 immunoreactive perikarya showing
ERa immunostaining was significantly decreased 1 month
after ovariectomy (50G3%) when compared with 1 week
after ovariectomy (67G5%; S.D., P!0.05).Discussion
Inflammation in the central nervous system is regulated by
resident glial cells and infiltrating immune cells (Ladeby et al.
2005, Pekny & Nilsson 2005). In this study, we have used an
animal model of peripheral inflammation elicited by the
systemic administration of LPS. The systemic LPS adminis-
tration has been previously described as a reliable method to
induce the activation of microglia in the rat brain (Buttini et al.
1996, Ng & Ling 1997, Semmler et al. 2005, Qin et al. 2007,
Sierra et al. 2007). The microglia respond to inflammatory
stimuli, such as LPS, with the retraction and thickening of the
cellular processes, swelling of the cell body, production of pro-
inflammatory cytokines and overexpression of myeloid
markers such as MHC-II (Ladeby et al. 2005). The expression
of MHC-II is considered as a reliable marker of microglia
activation. The MHC-II immunoreactivity is practically
undetectable in resting microglia, but reactive microglia cells
overexpress MHC-II in response to neurotoxins (Cevolani
et al. 2001), neural injury (Popovich et al. 1997, Hong et al.
2006) or inflammatory stimuli, such as LPS (Ng & Ling 1997,
Hauss-Wegrzyniak et al. 1998). In agreement with this, we
have detected a marked increase in the number of MHC-II
immunoreactive cells in the brain after systemic administration
of LPS. The MHC-II immunoreactive cells were particularly
abundant in white matter tracts and we selected the central
white matter of the cerebellum for the study. Themorphology
of the MHC-II immunoreactive cells, with swelled somas
and with retracted and thick processes, was the expected for
the activated microglia (Ladeby et al. 2005). As an additional
marker for inflammation, some sections from each experi-
mental group were immunostained with an anti-rat lysosomalJournal of Endocrinology (2008) 198, 219–230
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Figure 8 Colocalization of OX42 immunoreactivity (red) and ERa immunoreactivity (green) in the central
white matter of the cerebellum of ovariectomized female rats. (A–D) Control animal and (E–H) animal injected
with LPS 1 week after ovariectomy. (A and E) Examples of OX42 immunoreactive cells. (B and F) ERa
immunoreactivity in the same microscopic fields of (A and E) respectively. (C and G) Merge of the green and red
channels showing points of colocalization (yellow) of OX42 and ERa in the soma and cellular processes of
OX42 immunoreactive cells. (D and H) High magnification of the cells that are shown in (B and F) respectively.
LPS administration enhanced the localization of ERa immunoreactivity in the cell body. Scale bars, 10 mm.
Full colour version of this figure available via http://dx.doi.org/10.1677/JOE-07-0294.
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phagocytic marker and detects phagocytic microglia (Graeber
et al. 1990, Bauer et al. 1994). Similar qualitative results were
obtained with both MHC-II and ED1 antibodies.
Previous studies have shown that microglia activation and
gene expression are affected by the ovarian hormone oestradiol.
Studies in microglia cultures have shown that oestradiol inhibits
the expression of inducible nitric oxide synthase and several
other inflammatory mediators in response to LPS and pro-
inflammatory cytokines (Bruce- Keller et al. 2000, 2001, Drew
&Chavis 2000,Vegeto et al. 2001,Baker et al. 2004,Dimayuga et
al. 2005). Studies in vivo have also demonstrated that oestradiol
reduces microglia reactivity and the expression of cytokines and
chemokines induced by an acute intracerebroventricular
injection of LPS in female mice (Vegeto et al. 2001, 2003,
2006). Oestradiol is also effective in reducing chronic microglia
activation around b-amyloid plaques in the brain of APP23
female mice, a model of Alzheimer’s disease (Vegeto et al. 2006)
and thehormone reducesmicroglia activation after a stabwound
injury in the hippocampus (Barreto et al. 2007). In agreement
with these previous findings, we have found in this study that
oestradiol decreases microglia activation after the systemic
administration of LPS. The effect of oestradiol was observed in
ovariectomized females and in intact males, indicating that the
hormonemay also participate in anti-inflammatoryeffects in the
male rat brain.
Our present findings also indicate that two SERMs currently
used for therapeutic purposes in humans, tamoxifen and
raloxifene, at doses within the range used in the clinical practice
(Bernstein et al. 1999, Palacios et al. 2004, Stovall et al. 2007), are
able to reducemicroglia activation in the central nervous systemJournal of Endocrinology (2008) 198, 219–230after systemic administration of LPS in males and females.
Previous studies have shown that tamoxifen and raloxifene
decrease the LPS-induced inflammatory response in microglial
cells in vitro (Suuronen et al. 2005) and that raloxifene decreases
the number of microglial cells in the brain of aged animals (Lei
et al. 2003). In addition, tamoxifen has been reported to reduce
rat brain damage after ischaemia in vivo (Kimelberg et al. 2003,
Mehta et al. 2003, Feng et al. 2004, Zhang et al. 2005) and both
tamoxifen and raloxifene prevent excitotoxic-induced neuronal
loss in the hippocampus of rats injected with kainic acid (Ciriza
et al. 2004). In addition, these SERMs exert neuroprotective
effects in different in vitromodels (Du et al. 2004, Benvenuti et al.
2005, Biewenga et al. 2005). Although in vitro studies indicate
that tamoxifen and raloxifene may have direct neuroprotective
effects on the neuronal cells (Du et al. 2004, Benvenuti et al.
2005, Biewenga et al. 2005), our findings suggest that both
SERMs may also exert in part its neuroprotective effects in vivo
by the regulation of microglia activation.
Although the response of microglia to oestradiol and SERMs
was, in general, similar between males and females treated 1
week and 1 month after ovariectomy, we have detected some
interesting differences. For instance, the doses of oestradiol
effective in decreasing microglia reactivity were not the same in
males and females. In addition, raloxifene had per se a moderate
pro-inflammatory action in females but not in males. These
differences suggest that the very different endocrine status of
gonadally intactmales andovariectomized femalesmay affect the
pro- and anti-inflammatory response to oestrogenic
compounds. The differences may also reflect a sexually
dimorphic response of microglia to oestrogenic ligands. In
addition, although both tamoxifen and raloxifene were able towww.endocrinology-journals.org
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tamoxifen was detected at all the doses tested, while raloxifene
lost its anti-inflammatory effects at the highest studied dose
(2 mg/kg b.w.) in animals treated 1 week after ovariectomy.
Interestingly, a previous study examining the neuroprotective
effect of similar doses of these two SERMs in vivo showed that
tamoxifen was neuroprotective at all the doses tested, while
raloxifene loses neuroprotective potency at the dose of 2 mg/kg
b.w. (Ciriza et al. 2004). Therefore, tamoxifen seems to have a
better anti-inflammatory profile in the brain than raloxifene.On
the other hand, the moderate pro-inflammatory action of
raloxifene in the brain of females that were not treated with LPS
suggests that some oestrogenic compounds may have a negative
impact in healthy brain, even if they are able to decrease brain
inflammation under pathological conditions. This possibility,
merits to be further explored in detail, and may be highly
relevant for human therapy and for the interpretation of the
neurological outcome of randomized clinical trials in which
oestrogenic compounds are administered to asymptomatic post-
menopausal women.
Our present findings, showing that oestrogenic compounds
are able to reduce microglia activation after systemic
inflammation, are complementary to previous studies in vivo,
in which oestradiol has been shown to reduce microglia
activation after local brain inflammation (Vegeto et al. 2001,
2003, 2006). In our study, the activation of microglia was
probably secondary to peripheral inflammation since there is a
reduced passage of peripheral LPS through the blood–brain
barrier (Nadeau & Rivest 1999). The systemic pro-
inflammatory cytokines, such as tumour necrosis factor-a,
are critical for the transfer of the peripheral inflammation
induced by LPS to the central nervous system (Qin et al.
2007). These pro-inflammatory cytokines cross the blood–
brain barrier and activate microglia and astroglia to produce
more inflammatory factors (Laye et al. 1994, Pitossi et al. 1997,
Eriksson et al. 2000, Combrinck et al. 2002, Choi et al. 2003,
Zuurman et al. 2003, Sierra et al. 2007), which will finally
cause chronic inflammation in the central nervous system
and progressive neurodegeneration (Perry et al. 2003,
Cunningham et al. 2005, Semmler et al. 2005, Qin et al.
2007). Therefore, in our model, oestrogenic compounds may
potentially reduce microglia activation and brain damage by
decreasing the peripheral release of pro-inflammatory
molecules. In addition, oestrogenic compounds may also
cross the blood–brain barrier and act directly on the
cerebellum to reduce the inflammatory effect of peripheral
cytokines. Indeed, oestradiol has been shown to reduce
inflammatory activation in primary microglia cultures and in
microglia cell lines that express ERs (Bruce-Keller et al. 2000,
2001, Drew & Chavis 2000, Vegeto et al. 2001, Baker et al.
2004, Dimayuga et al. 2005). Previous studies have detected
the expression of ERb in microglia in the hippocampus of
monkeys after cerebral ischaemia (Takahashi et al. 2004) and
ERa in microglia isolated from the brain of adult mice (Sierra
et al. 2008). Our present findings suggest that microglial cells
in the rat cerebellum, in vivo, express ERa but apparently notwww.endocrinology-journals.orgERb, although it cannot be excluded that ERb is expressed
by cerebellar microglia at levels too low to be detected by
classical immunohistochemical techniques. The spotted
localization of ERa immunoreactivity in the cellular
processes and in the perikaryon of microglial cells agrees
with previous findings by electron microscopic immuno-
detection of ERa in the hippocampus of mice (Sierra et al.
2008) and is compatible with non classical ER-mediated
mechanisms of action, activating membrane and/or cyto-
plasmic signalling (Beyer et al. 2003, Kelly et al. 2005, Marin
et al. 2005, Suuronen et al. 2005). In this regard it is of interest
that in macrophages, oestradiol exerts an anti-inflammatory
effect by a non-classical mechanism of action, which involves
the activation of phosphatidylinositol 3-kinase that in turn is
mediated by ERa, and not by ERb (Ghisletti et al. 2005).
Furthermore, central anti-inflammatory actions of oestradiol
after intracerebral injection of LPS are at loss in ERaKOmice
(Vegeto et al. 2003), suggesting that ERa expressed by brain
cells is involved in the oestrogenic effect.
Sierra et al. (2008) have recently detected a decrease in the
mRNA levels of ERa in microglia isolated from the brain of
mice treated with LPS, indicating that ERa expression in
microglia is regulated by inflammatory challenge. In
agreement with this, we have found that LPS regulates
ERa immunoreactivity in rat cerebellar microglia. However,
in our study, we have detected an increase in the percentage of
microglial cells immunoreactive for ERa, while Sierra et al.
(2008) detected a decrease in mRNA levels in microglia.
Among other possible causes, such as the different time
courses of the analysis after exposure to LPS, hours in the case
of the study of Sierra et al. (2008) and days in our study, may
explain the apparent discrepancy. However, further studies are
necessary to determine the precise time course of ERa
changes in microglia after immune challenge. Our results also
suggest that the duration of hormone deprivation may affect
the action of LPS on ERa immunoreactivity and that some
oestrogenic compounds, such as 17b-oestradiol and tamox-
ifen, may regulate the amount of ERa in the perikarya of
microglial cells in animals treated 1 week after ovariectomy.
This effect may be mediated by changes in the expression
and/or the intracellular localization of ERa in microglia.
Furthermore, 17b-oestradiol counteracts the effect of LPS on
the distribution of ERa immunoreactivity in microglia in
animals treated 1 week after ovariectomy. These findings
suggest that ERa is involved in the response of microglia to
LPS and oestrogenic compounds. Therefore, at least a part of
the anti-inflammatory effects of oestrogenic compounds in
the brain may be exerted by a direct effect on microglial cells
expressing ERa. In addition, oestrogenic compounds may act
on ERs expressed in other cerebellar cells such as Purkinje
neurons, which are shown in this and previous studies
(Shughrue et al. 1997, Price & Handa 2000), express ERb.
The axons of Purkinje neurons cross the central white matter
of the cerebellum, and therefore their functional interaction
with microglia in this location is conceivable. Afferent axonsJournal of Endocrinology (2008) 198, 219–230
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transmit indirectly oestrogenic signals to microglia.
Finally, our findings in females showing an impairment of
the anti-inflammatory action of raloxifene, at the dose of
1 mg/kg b.w., 1 month after ovariectomy, in comparison with
its anti-inflammatory activity 1 week after ovariectomy,
indicate that previous duration of ovarian hormonal
deprivation may affect the anti-inflammatory effects of some
SERMs. Endocrine induced changes in the expression of ERs
or cofactors for ER transcription in the neural cells may be
the cause of this difference. Indeed, our findings suggest that
the basal expression of ERa in microglia is reduced and its
response to LPS is extinct by 1 month after ovariectomy
when compared with 1 week after ovariectomy. In addition,
raloxifene did not affect the localization of ERa in microglia
in animals treated with LPS 1 week after ovariectomy, but
decreased the localization of ERa in microglia in animals
treated with LPS 1 month after ovariectomy. The modifi-
cation in the response of raloxifene with the duration of the
deprivation of ovarian hormones may have relevance for
therapeutic use of this SERM. Interestingly, a recent study has
shown that oestrogen treatment given immediately at the time
of ovariectomy in rodents attenuates central and peripheral
production of pro-inflammatory cytokines after ischaemic
stroke. By contrast, oestradiol did not suppress production of
pro-inflammatory molecules when it was administered after
10-week postovariectomy (Suzuki et al. 2007). Therefore, the
neuroprotective and anti-inflammatory actions of oestradiol
and oestrogenic compounds may be affected by the duration
of the deprivation of ovarian hormones and this may at least
partially explain the differences observed in the outcome of
hormonal therapy between peri- and post-menopausal
women (Maki 2005, Miller et al. 2005).
In summary, our findings indicate that 17b-oestradiol and
the SERMs tamoxifen and raloxifene reduce microglia
activation in male and female rats, after peripheral inflam-
mation induced by LPS administration, by a mechanism that
may involve ERs in microglia. While tamoxifen reduced
microglia activation at all the doses tested, raloxifene lost anti-
inflammatory activity at high doses and had moderate pro-
inflammatory effects per se in female brains. Furthermore, in
females, previous duration of ovarian hormonal deprivation
affects the anti-inflammatory action of raloxifene. These
findings indicate that the modulation of the activity of ERs
using SERMs represents a potential therapeutic approach to
reduce microglia activation and central nervous system
damage after systemic inflammation and suggest that previous
duration of ovarian hormonal deprivation may affect the
activity of some oestrogenic compounds on microglia.Declaration of Interest
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